In 1995, the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) (collectively, the Agencies) published guidelines that delineated how and when the Agencies would evaluate intellectual property licensing...more
Following several other circuits as well as patent law precedent, in SunEarth, Inc. v. Sun Earth Solar Power Co., the U.S. Court of Appeals for the Ninth Circuit recently made it easier for Lanham Act litigants to recover...more
11/18/2016
/ Appeals ,
Attorney's Fees ,
Contempt ,
Exceptional Case ,
Lanham Act ,
Octane Fitness v. ICON ,
Patent Act ,
Preliminary Injunctions ,
Solar Energy ,
Solar Panels ,
Trademark Infringement ,
Trademark Trial and Appeal Board ,
Trademarks
Patent settlement agreements were traditionally deemed outside the purview of antitrust scrutiny unless the patent holder’s conduct fell outside the legitimate scope of the patent’s exclusionary power. This all changed when...more
7/5/2016
/ Abbreviated New Drug Application (ANDA) ,
AbbVie ,
Actavis Inc. ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
FTC v Actavis ,
Generic Drugs ,
Hatch-Waxman ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Reverse Payment Settlement Agreements ,
SCOTUS ,
SmithKline Beecham ,
Warner Chilcott